FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892030431> ?p ?o ?g. }

• W2892030431 endingPage "328" @default.
• W2892030431 startingPage "320" @default.
• W2892030431 abstract "Abstract Background We analyzed long-term quality of life (QoL) and prognostic factors for QoL as well as clinical outcome in patients with advanced cervical cancer (ACC) treated with primary radiochemotherapy (RChT) consisting of external beam radiotherapy (EBRT) with or without sequential or simultaneous integrated boost (SIB) to the parametria, intracavitary brachytherapy and concomitant chemotherapy (ChT). Patients and methods Eighty-three women were treated with primary RChT between 2008 and 2014. Survival of all patients was calculated and prognostic factors for survival were assessed in univariate and multivariate analysis. In 31 patients QoL was assessed in median 3 years (range 2–8 years) after treatment. QoL was compared to published normative data and the influence of age, tumour stage, treatment and observed acute toxicities was analyzed. Results Thirty-six patients (43.4%) died, 18 (21.7%) had a local recurrence and 24 (28.9%) had a distant progression. Parametrial boost (p = 0.027) and ChT (p = 0.041) were independent prognostic factors for overall survival in multivariate analysis. Specifically, a parametrial equivalent doses in 2-Gy fractions (EQD2) > 50 Gy was associated with an improved overall survival (OS) (p = 0.020), but an EQD2 > 53 Gy did not further improve OS (p = 0.194). Tumour size was the only independent prognostic factor for local control (p = 0.034). Lymph node status (p = 0.038) and distant metastases other than in paraaortic lymph nodes (p = 0.002) were independent prognostic factors for distant progressionfree survival. QoL was generally inferior to the reference population. Age only correlated with menopausal symptoms (p = 0.003). The degree of acute gastrointestinal (p = 0.038) and genitourinary (p = 0.041) toxicities correlated with the extent of chronic symptom experience. Sexual/vaginal functioning was reduced in patients with larger tumours (p = 0.012). Parametrial EQD2 > 53 Gy correlated with reduced sexual/vaginal functioning (p = 0.009) and increased sexual worry (p = 0.009). Whether parametrial dose escalation was achieved by sequential boost or SIB, did not affect survival or QoL. Conclusions Primary RChT is an effective treatment, but long-term QoL is reduced. The degree of acute side effects of RChT correlates with the extent of chronic symptoms. Patients benefit from parametrial SIB or sequential boost, but an EQD2 > 53 Gy does not further improve survival and negatively affects QoL." @default.
• W2892030431 created "2018-09-27" @default.
• W2892030431 creator A5032461123 @default.
• W2892030431 creator A5041527082 @default.
• W2892030431 creator A5053516632 @default.
• W2892030431 creator A5061995639 @default.
• W2892030431 creator A5072787929 @default.
• W2892030431 creator A5073433605 @default.
• W2892030431 creator A5078003238 @default.
• W2892030431 creator A5090066209 @default.
• W2892030431 date "2018-09-01" @default.
• W2892030431 modified "2023-10-06" @default.
• W2892030431 title "Percutaneous parametrial dose escalation in women with advanced cervical cancer: feasibility and efficacy in relation to long-term quality of life" @default.
• W2892030431 cites W1975099157 @default.
• W2892030431 cites W2000339116 @default.
• W2892030431 cites W2009661592 @default.
• W2892030431 cites W2014343721 @default.
• W2892030431 cites W2015584911 @default.
• W2892030431 cites W2019503369 @default.
• W2892030431 cites W2020843880 @default.
• W2892030431 cites W2027276382 @default.
• W2892030431 cites W2042262831 @default.
• W2892030431 cites W2065787368 @default.
• W2892030431 cites W2071906513 @default.
• W2892030431 cites W2077617763 @default.
• W2892030431 cites W2088021312 @default.
• W2892030431 cites W2107088910 @default.
• W2892030431 cites W2118926207 @default.
• W2892030431 cites W2122321342 @default.
• W2892030431 cites W2131860931 @default.
• W2892030431 cites W2136659491 @default.
• W2892030431 cites W2157372207 @default.
• W2892030431 cites W2199006423 @default.
• W2892030431 cites W2222645822 @default.
• W2892030431 cites W2264664000 @default.
• W2892030431 cites W2314753133 @default.
• W2892030431 cites W2324392028 @default.
• W2892030431 cites W2341208453 @default.
• W2892030431 cites W2345268804 @default.
• W2892030431 cites W2408917143 @default.
• W2892030431 cites W2520600536 @default.
• W2892030431 cites W2549947571 @default.
• W2892030431 cites W2783123637 @default.
• W2892030431 doi "https://doi.org/10.2478/raon-2018-0029" @default.
• W2892030431 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6137362" @default.
• W2892030431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30210042" @default.
• W2892030431 hasPublicationYear "2018" @default.
• W2892030431 type Work @default.
• W2892030431 sameAs 2892030431 @default.
• W2892030431 citedByCount "2" @default.
• W2892030431 countsByYear W28920304312021 @default.
• W2892030431 crossrefType "journal-article" @default.
• W2892030431 hasAuthorship W2892030431A5032461123 @default.
• W2892030431 hasAuthorship W2892030431A5041527082 @default.
• W2892030431 hasAuthorship W2892030431A5053516632 @default.
• W2892030431 hasAuthorship W2892030431A5061995639 @default.
• W2892030431 hasAuthorship W2892030431A5072787929 @default.
• W2892030431 hasAuthorship W2892030431A5073433605 @default.
• W2892030431 hasAuthorship W2892030431A5078003238 @default.
• W2892030431 hasAuthorship W2892030431A5090066209 @default.
• W2892030431 hasBestOaLocation W28920304311 @default.
• W2892030431 hasConcept C121608353 @default.
• W2892030431 hasConcept C126322002 @default.
• W2892030431 hasConcept C126894567 @default.
• W2892030431 hasConcept C141071460 @default.
• W2892030431 hasConcept C143998085 @default.
• W2892030431 hasConcept C144301174 @default.
• W2892030431 hasConcept C159110408 @default.
• W2892030431 hasConcept C2776694085 @default.
• W2892030431 hasConcept C2777416452 @default.
• W2892030431 hasConcept C2778220009 @default.
• W2892030431 hasConcept C2779384505 @default.
• W2892030431 hasConcept C2779951463 @default.
• W2892030431 hasConcept C2780813298 @default.
• W2892030431 hasConcept C2780849966 @default.
• W2892030431 hasConcept C2910158674 @default.
• W2892030431 hasConcept C2993195994 @default.
• W2892030431 hasConcept C38180746 @default.
• W2892030431 hasConcept C509974204 @default.
• W2892030431 hasConcept C71924100 @default.
• W2892030431 hasConceptScore W2892030431C121608353 @default.
• W2892030431 hasConceptScore W2892030431C126322002 @default.
• W2892030431 hasConceptScore W2892030431C126894567 @default.
• W2892030431 hasConceptScore W2892030431C141071460 @default.
• W2892030431 hasConceptScore W2892030431C143998085 @default.
• W2892030431 hasConceptScore W2892030431C144301174 @default.
• W2892030431 hasConceptScore W2892030431C159110408 @default.
• W2892030431 hasConceptScore W2892030431C2776694085 @default.
• W2892030431 hasConceptScore W2892030431C2777416452 @default.
• W2892030431 hasConceptScore W2892030431C2778220009 @default.
• W2892030431 hasConceptScore W2892030431C2779384505 @default.
• W2892030431 hasConceptScore W2892030431C2779951463 @default.
• W2892030431 hasConceptScore W2892030431C2780813298 @default.
• W2892030431 hasConceptScore W2892030431C2780849966 @default.
• W2892030431 hasConceptScore W2892030431C2910158674 @default.
• W2892030431 hasConceptScore W2892030431C2993195994 @default.
• W2892030431 hasConceptScore W2892030431C38180746 @default.
• W2892030431 hasConceptScore W2892030431C509974204 @default.

• next